Safusidenib is intended for the treatment of Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 glioma. Credit: Wichudapa/Shutterstock.com.

AnHeart Therapeutics has dosed the first patient in the Phase II G203 clinical trial of safusidenib to treat Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma.

The two-part, open-label, multicentre study is designed to assess the safety and efficacy of the mIDH1 inhibitor safusidenib as a single agent in patients with WHO Grade 2 or Grade 3 IDH1-mutant glioma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Part 1 of the study will determine the optimal dose of safusidenib while Part 2 will assess the safety and efficacy.

Approximately 95 patients will be enrolled in the study. The company is currently enrolling patients from the US with plans to expand enrolment to other countries.

Favourable anti-tumour activity was demonstrated in a Phase I clinical trial in glioma patients.

Objective response rate of 33% (4/12) and 17% (6/35) was observed in patients with contrast non-enhancing and enhancing tumours, respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Safusidenib also showed a tolerable safety profile. 43% of patients treated showed at least one Grade 3 treatment emergent AE. No Grade 4 or 5 AEs or serious treatment-related AEs were observed in the trial.

AnHeart CEO Jerry Wang said: “This marks an important milestone for AnHeart, as we now have two investigational precision therapies in late-stage clinical trials.

“Our mission is to improve the lives of people with cancer. Our strategy is to target known genetic drivers of cancer with the goal of bringing next-generation medicines that raise the bar for what patients should expect from cancer treatment.

“We look forward to sharing additional updates as we continue to progress our clinical programmes.”

In 2020, AnHeart licensed safusidenib from Daiichi Sankyo and owns its worldwide rights, excluding Japan where the latter retains development and commercial rights.